Quarterly report [Sections 13 or 15(d)]

Segment Information (Details)

v3.25.1
Segment Information (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
USD ($)
segment
Mar. 31, 2024
USD ($)
segment
Segment Information    
Number of reportable segments | segment 1 1
Operating expenses:    
Total operating expenses $ 11,149 $ 10,948
Segment Reporting, Other Segment Item, Composition, Description Other Segment Items include interest income, foreign currency exchange loss, and loss on common stock warrant liabilities. Other Segment Items include interest income, foreign currency exchange loss, and loss on common stock warrant liabilities.
Net Loss $ (11,212) $ (10,945)
Immunotherapy and targeted oncology therapy    
Operating expenses:    
Employee Expenses 2,463 2,109
Stock-based Compensation 1,956 709
Fortress Founder's Agreement and MSA Expenses 177 521
Manufacturing and Development Expenses 352 4,442
Clinical Expenses 605 1,300
Regulatory Expenses 20 303
License Fees 93 50
Legal & Accounting Expense 3,137 643
R&D Other Expense 134 275
G&A Other Expense 2,212 596
Total operating expenses 11,149 10,948
Other Segment Items (63) 3
Net Loss $ (11,212) $ (10,945)